Janssen Pharmaceutica Nv

Janssen Biotech, Inc.

Jannsen Pharmaceutica Bv

John M Keith

Natalie Anne Hawryluk

William Moore Jones

Steven P Meduna

Jing Liu

Neelakandha S Mani

Michael D Hack

Alec D Lebsack

Wendy Eccles

Kelly J McClure

Paul J Krawczuk

Mark D Rosen

Anne E Fitzgerald

Michael Anthony Letavic

J Guy Breitenbucher

Alison L Chambers

Steven D Goldberg

Jeffrey E Merit

Mark S Tichenor

Mark Seierstad

Frank John Villani, Jr

Nicholas I Carruthers

Daniel J Pippel

Kiev S Ly

Genesis M Bacani

Richard Apodaca

Hua M Zhong

Chennagiri R Pandit

Alice Lee-Dutra

John E Mills

Zachary S Sales

Amy K Timmons

Ronald L Wolin

Wei Zhang

Timothy W Lovenberg

Rhys Salter

Emily M Stocking

Xiaohua Xue

Shalom Goldberg

Fengbin Song

Douglas Behenna

Ann J Barbier

David A Kummer

Wei Xiao

Cheryl A Grice

Chandravadan R Shah

Xiaohu Deng

Brett D Allison

Virginia M Tanis

Michael P Curtis

Jill A Jablonowski

Connor L Martin

Stefan McCarver

Vadim Dudkin

Alexander Valdes

Timothy B Rhorer

Leslie A Gomez

Craig R Woods

Charlotte Pooley Deckhut

Hua Zhong

Alexander Raymond Rovira

Steven Loskot

Joan M Pierce

Frank J Villani, Jr

Mark J Sierestad

Jennifer M B Miller

Alexander Rovira

Kelly J Mcclure

Macrocyclic chelators for chelation of alpha-emitting radiometal ions, such as actinium-225 are provided. Also provided are radiometal complexes containing an alpha-emitting radiometal ion bound to the macrocyclic chelator via coordinate bonding, and radioimmunoconjugates containing the radiometal complexes covalently linked to a targeting ligand, such as an antibody or antigen binding fragment thereof. The radioimmunoconjugates can be produced by click chemistry reactions. Methods of using the radiocomplexes and radioimmunoconjugates for selectively targeting neoplastic cells for radiotherapy and for treating neoplastic diseases and disorders are also described.

Macrocyclic chelators and methods of use thereof

The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R, R, R, Rand Rare defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.

Imidazopyridazines as modulators of IL-17

The present invention relates to compounds of Formula (I), or a form thereof, wherein ring A, R, L and Rare as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention. 

Flap modulators

The present invention relates to compounds of Formula (I), or a form thereof, wherein ring A, R, L and Rare as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.

The present invention relates to compounds of Formula (I), or a form thereof, wherein ring A, R, R, R, R', L, W, and V are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.

FLAP modulators

The present invention relates to compounds of Formula (I), or a form thereof wherein ring A, R, R, R, R', L, W, and V are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention. 

4-(2,2-Difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl)-amide is described, which is useful as a FAAH modulator. 4-(2,2-Difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl)-amide may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis). A method of synthesizing 4-(2,2-difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl)-amide is also disclosed.

Modulators of fatty acid amide hydrolase

Certain substituted pyridyl amide compounds are histamine Hreceptor modulators useful in the treatment of histamine Hreceptor-mediated diseases.

Substituted pyridyl amide compounds as modulators of the histamine H3 receptor

[object Object]

Growing community of inventors

San Diego, CA, United States of America

John M Keith